Место фиксированной комбинации бронходилататоров длительного действия тиотропий / олодатерол в стартовой терапии хронической обструктивной болезни легких. Заключение Совета экспертов Российского респираторного общества


https://doi.org/10.18093/0869-0189-2016-26-4-505-513

Полный текст:


Аннотация

.

Список литературы

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for di-agnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2016. www.goldcopd.org

2. Miravitlles M., Worth H., Soler Cataluña J.J. et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir. Res. 2014; 15: 122–127.

3. Lange P., Marott J.L., Vestbo J. et al. Prediction of the clinical course of chronic obstruc-tive pulmonary disease, using the new GOLD classification: a study of the general population. Am. J. Respir. Crit. Care Med. 2012; 186 (10): 976–981.

4. Nishimura К., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121: 1434–1440.

5. Troosters T., Sciurba F., Battaglia S. et al. Physical inactivity in patients with COPD, a controlled multicenter pilot-study. Respir. Med. 2010; 104: 1005−1011.

6. Donaire-Gonzalez D., Gimeno-Santos E., Balcells E. Physical activity in COPD patients: patterns and bouts. Eur. Respir. J. 2013; 42: 993–1002.

7. Waschki B., Kirsten A., Holz O. et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011; 140: 331–342.

8. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15-61.

9. Lee J.-H., Lee Y.K., Kim E.-K. et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir. Med. 2010; 104: 542–549.

10. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 8 (361): 449–456.

11. Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 2013; 1 (1): 51–60.

12. Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomized, double blind placebo con-trolled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE-trial. Br. Med. J. 2000; 320 (7245): 1297–1303.

13. Soriano J.B., Sin D.D., Zhang X. et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest. 2007; 131 (3): 682–689.

14. Wedzicha J.A., Calverley P., Seemunqal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19–26.

15. Wedzicha J.A., Banerji D., Chapman K. R. et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD.N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/NEJMoa1516385.

16. Incalzi R.A., Caradonna P., Ranieri P. et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir. Med. 2000; 94 (11): 1079–1084.

17. Singh S., Amin A.V., Loke Y.K. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. Arch. Int. Med. 2009; 169: 219–229.

18. Yawn B.P., Li Y., Tian H. et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 295–304.

19. Lapi F., Kezouh A., Suissa S., Ernst P. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur. Respir. J. 2013; 42: 79–86.

20. Tashkin D.P. et al. UPLIFT study investigators. N. Engl. J. Med. 2008; 359: 1543–1554.

21. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. COPD. 2014; 9: 963–974.

22. Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации Американской коллегии торакальных врачей и Канадского торакального общества (часть 1-я). Пульмонология. 2016; 2: 155.

23. Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации Американской коллегии торакальных врачей и Канадского торакального общества (часть 2-я). Пульмонология. 2016; 3: 170.

24. Decramer M., Celli B., Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecied subgroup analysis of a randomised controlled trial. Lancet. 2009; 374: 1171–1178.

25. Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat Inhaler and the Risk of Death in COPD: The TIOSPIR Trial. N. Engl. J. Med. 2013; 369 (10): 1491–501.

26. Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364: 1093–1103.

27. Bateman E.D., Tashkin D., Siafakas N. et al. A one year trial of tiotropium Respimat® plus usual therapy in COPD patients. Resp. Med. 2010; 104: 1460–1472.

28. Decramer M.L., Chapman K.R., Dahl R. et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir. Med. 2013; 1 (7): 524–533.

29. Frampton J.E. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014; 74 (4): 465–488.

30. Beeh K.-M., Westerman J., Kirsten A.-M. et al. The 24-h lung function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2015; 32: 53–59.

31. Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur. Respir. J. 2015; 45: 969–979.

32. Ferguson G.T., Flezar M., Korn S. et al. Efficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv. Ther. 2015; 32: 523–536.

33. Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 2015; 109: 1312–1319.

34. Profita M., Bonanno A., Montalbano A.M. et al. β2-Long-acting and anticholinergic drugs control TGF β1-mediated neutrophilic inflammation in COPD. Biochim. Biophys. Acta. 2012; 1822: 1079–1089.

35. Авдеев С.Н. Новые возможности использования тиотропия бромида с помощью аэрозольного устройства доставки – ингалятора Респимат. Пульмонология. 2013; 5: 70–80.

36. Martinez F.J., Abrahams R., Ferguson G.T. et al. Effects of symptom severity at baseline on lung-function and SGRQ responses in the OTEMTO® studies. Am. J. Respir. Crit. Care Med. 2016; 193: A6787.

37. Buhl R., McGarvey L., Korn S. et al. Benefits of tiotropium + olodaterol over tiotropium at delaying clinically significant events in patients with COPD classified as GOLD B. Am. J. Respir. Crit Care Med. 2016; 193: A6779.

38. Singh D., Gaga M., Schmidt O. et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respir. Res. 2016; 17: 73.

39. Чазова И. Е., Чучалин А. Г., Зыков К. А., Ратова Л. Г. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Рекомендации Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. 2013; 10 (1): 5–34.

40. Celli B., Decramer M., Kesten S. et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 948–955.

41. Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–501.

42. Jenkins C.R. More than just reassurance on tiotropium safety. N. Engl. J. Med. 2013; 369 (16): 1555–1556.

43. Cave A.C., Hurst M.M. The use of long acting β2-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis. Pharmacol. Ther. 2011; 130: 114–143.

44. Lahousse L., Verhamme K., Stricker B., Brusselle G. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir. Med. 2016; 4: 149–164.


Дополнительные файлы

Для цитирования: Авдеев С.Н., Айсанов З.Р., Белевский А.С., Зыков К.А., Лещенко И.В., Овчаренко С.И., Шмелев Е.И., Архипов В.В., Горблянский Ю.Ю., Емельянов А.В., Игнатова Г.Л., Казанцев В.А., Кароли Н.А., Колбасников С.В., Куделя Л.М., Кузубова Н.А., Синопальников А.И., Степанян И.Э., Трофименко И.Н., Фассахов Р.С., Хамитов Р.Ф., Шапорова Н.Л. Место фиксированной комбинации бронходилататоров длительного действия тиотропий / олодатерол в стартовой терапии хронической обструктивной болезни легких. Заключение Совета экспертов Российского респираторного общества.  Пульмонология. 2016;26(4):505-513. https://doi.org/10.18093/0869-0189-2016-26-4-505-513

For citation: Avdeev S.N., Aisanov Z.R., Belevskiy A.S., Zykov K.A., Leshchenko I.V., Ovcharenko S.I., Shmelev E.I., Arkhipov V.V., Gorblyanskiy Y.Y., Emel'yanov A.V., Ignatova G.L., Kazantsev V.A., Karoli N.A., Kolbasnikov S.V., Kudelya L.M., Kuzubova N.A., Sinopal'nikov A.I., Stepanyan I.E., Trofimenko I.N., Fassakhov R.S., Khamitov R.F., Shaporova N.L. A role of long-acting bronchodilator tiotropium / olodaterol fixed combination as the first-line therapy of chronic obstructive pulmonary disease. A Consensus of Expert Board of Russian Respiratory Society. Russian Pulmonology. 2016;26(4):505-513. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-4-505-513

Просмотров: 443

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)